Buy Ocular on NDA Momentum for AXPAXLI — Binary, But Compelling Risk/Reward
Ocular has signaled that AXPAXLI, its wet-AMD program, is moving toward a potential NDA filing. That development makes the stock an actionable buy for traders who can tolerate clinical-stage binary risk. The trade below balances upside to regulatory success with a conservative stop to limit downside from filing delays, safety flags, or commercial r…